KDM3A,JMJD1A antibody

References :
Uemura M, Yamamoto H, Takemasa I. Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(18):4636-46. 2010. Oh HS, Bryant KF, Nieland TJ. A targeted RNA interference screen reveals novel epigenetic factors that regulate herpesviral gene expression. mBio. 5(1):e01086-13. 2014. Kasioulis I, Syred HM, Tate P. Kdm3a lysine demethylase is an Hsp90 client required for cytoskeletal rearrangements during spermatogenesis. Molecular biology of the cell. 25(8):1216-33. 2014. Ueda J, Ho JC, Lee KL. The hypoxia-inducible epigenetic regulators Jmjd1a and G9a provide a mechanistic link between angiogenesis and tumor growth. Molecular and cellular biology. 34(19):3702-20. 2014. Yamada D, Kobayashi S, Yamamoto H. Role of the hypoxia-related gene, JMJD1A, in hepatocellular carcinoma: clinical impact on recurrence after hepatic resection. Annals of surgical oncology. 19 Suppl 3:S355-64. 2012. Du ZM, Hu LF, Wang HY. Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic marker JMJD1A. PloS one. 6(4):e19137. 2011. Cho HS, Toyokawa G, Daigo Y. The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene. International journal of cancer. 131(3):E179-89. 2012. Kim KY, Huerta SB, Izumiya C. Kaposi’s sarcoma-associated herpesvirus (KSHV) latency-associated nuclear antigen regulates the KSHV epigenome by association with the histone demethylase KDM3A. Journal of virology. 87(12):6782-93. 2013.